Irbesartan
From Wikipedia, the free encyclopedia
 |
|
|
Irbesartan
|
|
| Systematic (IUPAC) name | |
| 2-butyl- 3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]- 1,3-diazaspiro[4.4]non-1-en-4-one |
|
| Identifiers | |
| CAS number | |
| ATC code | C09 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C25H28N6O |
| Mol. mass | 428.53 |
| Pharmacokinetic data | |
| Bioavailability | 60–80% |
| Metabolism | Hepatic (CYP2C9) |
| Half life | 11–15 hours |
| Excretion | Renal 20%, faecal 65% |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
D (Au) |
| Legal status | |
| Routes | Oral |
Irbesartan (INN) (IPA: [ɜrbəˈsatən]) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.
Contents |
[edit] Clinical use
[edit] Indications
As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,[1] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).[2]
[edit] Combination with diuretic
Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.
[edit] References
- ^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID 11565517.
- ^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
[edit] See also
Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Tasosartan, Telmisartan, Valsartan
